➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Express Scripts
McKinsey
Merck
Boehringer Ingelheim

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for LY3154207

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for LY3154207?

LY3154207 is an investigational drug.

There have been 7 clinical trials for LY3154207. The most recent clinical trial was a Phase 1 trial, which was initiated on November 10th 2017.

The most common disease conditions in clinical trials are Parkinson Disease, Dementia, and [disabled in preview]. The leading clinical trial sponsors are Eli Lilly and Company and [disabled in preview].

There is one US patent protecting this investigational drug and forty-six international patents.

Recent Clinical Trials for LY3154207
TitleSponsorPhase
A Study to Evaluate LY3154207 on the Brain of Healthy ParticipantsEli Lilly and CompanyPhase 1
A Drug Interaction Study of LY3154207 in Healthy ParticipantsEli Lilly and CompanyPhase 1
Study of LY3154207 in Healthy ParticipantsEli Lilly and CompanyPhase 1

See all LY3154207 clinical trials

Clinical Trial Summary for LY3154207

Top disease conditions for LY3154207
Top clinical trial sponsors for LY3154207

See all LY3154207 clinical trials

International Patents for LY3154207

Drugname Country Document Number Estimated Expiration Related US Patent
LY3154207 Argentina AR096310 2033-05-30   Start Trial
LY3154207 Australia AU2014274435 2033-05-30   Start Trial
LY3154207 Australia AU2016238934 2033-05-30   Start Trial
LY3154207 Brazil BR112015029090 2033-05-30   Start Trial
LY3154207 Canada CA2912849 2033-05-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Express Scripts
McKinsey
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.